Microwave-assisted synthesis and in vitro stability of N-benzylamide non-steroidal anti-inflammatory drug conjugates for CNS delivery

被引:4
作者
Eden, Brandon D. [1 ]
Rice, Andrew J. [1 ]
Lovett, Troy D. [1 ]
Toner, Olivia M. [1 ]
Geissler, Evan P. [1 ]
Bowman, William E. [1 ,2 ]
Young, Sherri C. [1 ]
机构
[1] Muhlenberg Coll, Dept Chem, 2400 Chew St, Allentown, PA 18104 USA
[2] Univ Delaware, Dept Chem & Biochem, 330 Delaware Circle, Newark, DE 19711 USA
关键词
Bioorganic chemistry; Inflammation; Prodrugs; Microwave-assisted synthesis; Drug delivery; CENTRAL-NERVOUS-SYSTEM; BRAIN-BARRIER SHUTTLE; ALZHEIMERS-DISEASE; PRODRUGS; INFLAMMATION; PEPTIDES; ACID; INDOMETHACIN; IBUPROFEN; ROFECOXIB;
D O I
10.1016/j.bmcl.2019.04.016
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
More effective delivery of non-steroidal anti-inflammatory drugs (NSAIDs) to the brain could treat the underlying inflammatory pathology of a range of CNS diseases and conditions. Use of a blood-brain barrier shuttle such as the N-benzylamide moiety, which has been largely unexplored for this purpose, could improve the brain bioavailabilities of NSAIDs. A series of novel N-benzylamide NSAID conjugates was synthesized via a three-step process with a microwave-assisted bimolecular nucleophilic substitution as the final step. We explored conditions to promote substitution over a competing elimination reaction, which was successfully suppressed with isopropyl alcohol solvent. All molecules exhibit physicochemical properties consistent with those of brain-penetrant molecules. Furthermore, they exhibit long ( > 48 h) half-lives in phosphate-buffered saline (PBS; pH 7.4) and short to moderate half-lives in human plasma. N-Benzylamide NSAID conjugates represent promising CNS drug discovery leads.
引用
收藏
页码:1487 / 1491
页数:5
相关论文
共 85 条
  • [1] Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression - A randomized controlled trial
    Aisen, PS
    Schafer, KA
    Grundman, M
    Pfeiffer, E
    Sano, M
    Davis, KL
    Farlow, MR
    Jin, S
    Thomas, RG
    Thal, LJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (21): : 2819 - 2826
  • [2] [Anonymous], 2015, Peptide chemistry and drug design
  • [3] Anslyn E. V., 2006, Modern physical organic chemistry
  • [4] Barbour R., Patent No. [WO 2015155694, 2015155694]
  • [5] Bohrmann B., 2014, [No title captured], Patent No. [WO 2014033074, 2014033074]
  • [6] Breitner JCS, 1996, NEUROBIOL AGING, V17, P789
  • [7] INVERSE ASSOCIATION OF ANTIINFLAMMATORY TREATMENTS AND ALZHEIMERS-DISEASE - INITIAL RESULTS OF A COTWIN CONTROL STUDY
    BREITNER, JCS
    GAU, BA
    WELSH, KA
    PLASSMAN, BL
    MCDONALD, WM
    HELMS, MJ
    ANTHONY, JC
    [J]. NEUROLOGY, 1994, 44 (02) : 227 - 232
  • [8] Extended results of the Alzheimer's disease anti-inflammatory prevention trial
    Breitner, John C.
    Baker, Laura D.
    Montine, Thomas J.
    Meinert, Curtis L.
    Lyketsos, Constantine G.
    Ashe, Karen H.
    Brandt, Jason
    Craft, Suzanne
    Evans, Denis E.
    Green, Robert C.
    Ismail, M. Saleem
    Martin, Barbara K.
    Mullan, Michael J.
    Sabbagh, Marwan
    Tariot, Pierre N.
    [J]. ALZHEIMERS & DEMENTIA, 2011, 7 (04) : 402 - 411
  • [9] Reactive Oxygen Species-Activated Nanoprodrug of Ibuprofen for Targeting Traumatic Brain Injury in Mice
    Clond, Morgan A.
    Lee, Bong-Seop
    Yu, Jeffrey J.
    Singer, Matthew B.
    Amano, Takayuki
    Lamb, Alexander W.
    Drazin, Doniel
    Kateb, Babak
    Ley, Eric J.
    Yu, John S.
    [J]. PLOS ONE, 2013, 8 (04):
  • [10] 2,5-Diketopiperazines as Neuroprotective Agents
    Cornacchia, C.
    Cacciatore, I.
    Baldassarre, L.
    Mollica, A.
    Feliciani, F.
    Pinnen, F.
    [J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2012, 12 (01) : 2 - 12